• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ESSA Pharma Inc.

    11/7/24 12:50:43 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EPIX alert in real time by email
    SC 13G 1 epix13g.htm


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.     )*

    ESSA Pharma Inc.
    (Name of Issuer)
     
    Common Shares, no par value per share
    (Title of Class of Securities)
     
    2966H708
    (CUSIP Number)
     
    November 1, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     BML Investment Partners, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     4,183,223
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     4,183,223
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     4,183,223
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     9.4%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
     
     
     
     
     

    Item 1(a). Name of Issuer:

     ESSA Pharma Inc.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

     Suite 720, 999 West Broadway, Vancouver, BC V5Z 1K5

    Item 2(a). Name of Person Filing:

     BML Investment Partners, L.P.
      

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     65 E Cedar, Suite 2, Zionsville, IN 46077

    Item 2(c). Citizenship:

     Delaware

    Item 2(d). Title of Class of Securities:

     Common Stock
     
    Item 2(e). CUSIP Number:

     29668H708


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) Amount beneficially owned: 4,183,223


    (b) Percent of class: 9.4%


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote: 0


    (ii) Shared power to vote or to direct the vote: 4,183,223

      (iii) Sole power to dispose or to direct the disposition of: 0

      (iv) Shared power to dispose or to direct the disposition of: 4,183,223
     


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    n/a
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     n/a

    Item 8. Identification and Classification of Members of the Group.

     n/a

    Item 9. Notice of Dissolution of Group.

     n/a
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 7, 2024
     
     
    BML Capital Management, LLC
     
     
    By:
     /s/ Braden M Leonard
       
    Name:  Braden M Leonard
       
    Title:  Managing Member of GP
     
     BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     

    Get the next $EPIX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EPIX

    DatePrice TargetRatingAnalyst
    11/4/2024Buy → Hold
    Jefferies
    11/4/2024Outperform → Perform
    Oppenheimer
    11/4/2024$15.00 → $2.00Overweight → Neutral
    Piper Sandler
    6/26/2023$17.00Outperform
    Oppenheimer
    8/17/2021$36.00 → $22.00Outperform
    Oppenheimer
    More analyst ratings

    $EPIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ESSA Pharma downgraded by Jefferies

    Jefferies downgraded ESSA Pharma from Buy to Hold

    11/4/24 8:34:37 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma downgraded by Oppenheimer

    Oppenheimer downgraded ESSA Pharma from Outperform to Perform

    11/4/24 7:26:24 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded ESSA Pharma from Overweight to Neutral and set a new price target of $2.00 from $15.00 previously

    11/4/24 7:26:03 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Essa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash Distribution

    SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that, in connection with the Company's recently announced return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the holders of common shares of the Company ("Common Shares" and the holders of such Common Shares, the "Shareholders") as part of the discontinuance and winding-up of the business of the Company pursuant to the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Co

    8/14/25 4:30:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Essa Pharma Inc. Announces US$80 Million Cash Distribution to Shareholders

    SOUTH SAN FRANCISCO, Calif and VANCOUVER, Canada, Aug. 6, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that, following the Company's receipt of an order from the Supreme Court of British Columbia (the "Court") on August 5, 2025, authorizing a reduction in the capital of the common shares of the Company (the "Common Shares" and the holders of such Common Shares, the "Shareholders") and concurrent distribution to the Shareholders, the board of directors of the Company (the "Board") has approved a return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the Shareholders as part of the discontinuance and win

    8/6/25 4:30:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders

    SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that, in connection with its previously announced business combination agreement with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of ESSA (the "Common Shares"), the Company intends to apply to the Supreme Court of British Columbia (the "Court") on August 5, 2025 for (i) an interim order authorizing the holding of a special meeting to consider and approve the Transaction (the "Interim Order") and (ii) for an order authorizi

    7/23/25 4:51:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Parkinson David Ross bought $21,213 worth of shares (9,223 units at $2.30), increasing direct ownership by 16% to 65,675 units (SEC Form 4)

    4 - ESSA Pharma Inc. (0001633932) (Issuer)

    12/18/23 9:57:03 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Berger Franklin M bought $133,274 worth of shares (23,259 units at $5.73), increasing direct ownership by 3% to 784,404 units (SEC Form 4)

    4 - ESSA Pharma Inc. (0001633932) (Issuer)

    11/22/23 6:22:47 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Berger Franklin M bought $419,661 worth of shares (76,471 units at $5.49), increasing direct ownership by 11% to 760,875 units (SEC Form 4)

    4 - ESSA Pharma Inc. (0001633932) (Issuer)

    11/16/23 5:45:43 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    SEC Filings

    View All

    SEC Form DEFA14A filed by ESSA Pharma Inc.

    DEFA14A - ESSA Pharma Inc. (0001633932) (Filer)

    8/14/25 4:55:58 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ESSA Pharma Inc. (0001633932) (Filer)

    8/14/25 4:40:26 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by ESSA Pharma Inc.

    10-Q - ESSA Pharma Inc. (0001633932) (Filer)

    8/13/25 6:59:23 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bvf Partners L P/Il exercised 2,920,000 in-the-money shares at a strike of $0.00 and sold $293 worth of shares (156 units at $1.88) (SEC Form 4)

    4 - ESSA Pharma Inc. (0001633932) (Issuer)

    8/7/25 4:36:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Biotech Growth N V sold $12,018,409 worth of shares (7,879,583 units at $1.53), closing all direct ownership in the company (SEC Form 4)

    4 - ESSA Pharma Inc. (0001633932) (Issuer)

    11/5/24 12:06:18 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Virsik Peter sold $4,185 worth of shares (694 units at $6.03), decreasing direct ownership by 8% to 7,776 units (SEC Form 4)

    4 - ESSA Pharma Inc. (0001633932) (Issuer)

    10/7/24 3:00:52 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    Leadership Updates

    Live Leadership Updates

    View All

    ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

    SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot

    3/6/25 7:00:00 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

    SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berg

    3/7/24 8:13:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

    SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin

    3/7/24 8:13:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    Financials

    Live finance-specific insights

    View All

    Essa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash Distribution

    SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that, in connection with the Company's recently announced return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the holders of common shares of the Company ("Common Shares" and the holders of such Common Shares, the "Shareholders") as part of the discontinuance and winding-up of the business of the Company pursuant to the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Co

    8/14/25 4:30:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

    SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that it has entered into a definitive agreement (the "Business Combination Agreement") with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of ESSA (the "Common Shares"). XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotechnology royalty aggregator, is acting as the structuring agent and will provide financing to Xeno for this Transaction. Under the terms of the Business Combi

    7/14/25 8:00:00 AM ET
    $EPIX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025

    Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025. "We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value," said David Parkinson, MD, President and CEO of ESSA. "We have taken productive steps tow

    5/8/25 7:00:00 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

    SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

    11/14/24 7:32:27 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

    SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

    11/14/24 4:04:37 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

    SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

    11/14/24 6:56:05 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care